Back to top
more

KalVista Pharmaceuticals (KALV)

(Delayed Data from NSDQ)

$11.74 USD

11.74
313,460

-0.15 (-1.26%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $11.76 +0.02 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KALV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

KalVista Pharmaceuticals, Inc. [KALV]

Reports for Purchase

Showing records 1 - 20 ( 105 total )

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

03/12/2024

Company Report

Pages: 8

First Oral On-Demand HAE Therapy on Horizon-Looking to NDA Expected 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

02/14/2024

Company Report

Pages: 8

Sebetralstat Delivers Positive On-Demand HAE Profile-Raising PT to $24; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

01/26/2024

Industry Report

Pages: 6

INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

12/08/2023

Company Report

Pages: 8

On-Demand HAE Oral Optionality Phase 3 KONFIDENT Topline Expected Early 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for KALV 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

09/08/2023

Company Report

Pages: 7

Near-Term 4Q23 Sebetralstat Readout From Phase 3 KONFIDENT Trial; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

07/10/2023

Company Report

Pages: 7

Sebetralstat Progress With Phase 3 KONFIDENT Readout Expected 4Q23; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

03/10/2023

Company Report

Pages: 7

Sebetralstat Confidence-Looking to Phase 3 KONFIDENT Trial 2H23; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

12/09/2022

Company Report

Pages: 7

Turning a New Page for Sebetralstat-Looking to Phase 3 Data 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

10/06/2022

Company Report

Pages: 7

Shifting Focus to On-Demand Sebetralstat, Distinction From KVD824; PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

09/09/2022

Company Report

Pages: 7

Plasma Kallikrein Inhibitor Platform Progress-Looking to Data in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

07/11/2022

Company Report

Pages: 7

Oral HAE On-Demand and Prophylaxis Progress, With Factor XIIa Inhibitor Upside

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

06/09/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

05/27/2022

Industry Report

Pages: 7

1Q2022 - Cash Balance and Upcoming Catalysts For Our Biotech Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

03/14/2022

Company Report

Pages: 5

FY3Q22 - Enrollment Progress in HAE in 2022 Tees Up Key Readouts in 2023

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

03/14/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

03/11/2022

Company Report

Pages: 7

KVD900 and KVD824-Two Shots on Goal for Oral HAE Therapeutics

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

03/09/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

12/13/2021

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: KalVista Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

12/10/2021

Company Report

Pages: 7

Oral Protease Inhibitor Advancement in HAE; Pivotal Phase 3 Positioned for 1Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party